Search
BCAL Diagnostics has partnered with researches in the United States to develop its blood-based breast cancer test technology.

Cancer move for local resources companies

Two Perth-based resources companies are planning to switch sectors with the acquisition of cancer-based biotechnology firms, with one planning a backdoor listing and the other seeking support for an IPO.

Spectrum Rare Earths has entered into an agreement to acquire Sydney-based BCAL Diagnostics (BCAL Dx), a biotech company that is developing a blood-based test for the presence of breast cancer.

BCAL Dx has partnered with a research team based in Kentucky, US, to develop the technology as a breast cancer screening test.

Login

(existing subscribers)

The password field is case sensitive.
Request new password

Register for free

Sign up here for free access to 7 articles per month + twice daily business email alerts.

CAPTCHA
Thanks! This question prevents spammers...
Image CAPTCHA
Enter the characters shown in the image.

Add your comment

Share Price

Closing price for the last 90 trading days
Source: Morningstar

Total Shareholder Return as at 29/09/17

1 year TSR5 year TSR
269thSpectrum Rare Earths16%-37%
719 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Source: Morningstar

Share Transactions

28/04/17
$65k Issued
28/04/17
$40k Issued
28/10/15
$58k Issued
Total value as at the date of the transaction
Source: Morningstar

Revenue

th-Spectrum Rare Earths$45k
489 listed resources companies ranked by revenue.
Source: Morningstar

Remuneration from Spectrum Rare Earths

1293rdAlexander Moyle$61k
1138thLeonid Charuckj$44k
Ranked by total remuneration from all listed WA companies

BNiQ Disclaimer